Kerasal® distribution expanded at Meijer and Hannaford

Opening orders received from 200 Meijer Hypermarket stores and 170 Hannaford Supermarkets

Moberg Pharma has received opening purchase orders from Hannaford Supermarkets for Moberg’s two leading Kerasal products, Kerasal Nail Fungal Nail Renewal Treatment and Kerasal Exfoliating Moisturizing Foot Ointment. Hannaford is an American supermarket chain with over 170 stores in New England as well as in upstate New York. The chain is owned by Delhaize America, which owns over 1,500 stores along the Eastern Seaboard. These Kerasal SKUs are expected to be on shelf at Hannaford stores in August.

Today Moberg Pharma also confirmed purchase orders for new distribution of Kerasal Nail at Meijer stores. Meijer is regional American hypermarket chain with about half of the company's 200 stores are located in Michigan and additional locations in Illinois, Indiana, Ohio, and Kentucky.  Meijer is a long time valued customer of Moberg Pharma North America, and has carried the company’s leading Kerasal and JointFlex products for many years. With distribution of Kerasal Nail well established and selling through at record rates in major national chains, the company is now focusing efforts on filling in distribution gaps at regional chains, which will further strengthen the Kerasal Nail brand.

About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with direct sales through its own sales organization in the US and sales through distributors in more than 35 countries. The company’s product portfolio includes topical products for the treatment of skin disorders and pain under the brands Kerasal®, Jointflex®, Kerasal Nail®and Kaprolac®. Kerasal Nail®(Nalox™ in many markets) is the leading product for the treatment of nail disorders in the Nordic market. The portfolio is developed further through acquisitions and in-licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.se.

About Us

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The ompany’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, NewSkin®, Dermoplast®, Domeboro®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).For further information, please visit: www.mobergpharma.com.

Contacts

Subscribe